A frequency, not a pill
In a college town in New Hampshire, between a green and a river, sits a 15-person company trying to treat cancer with radio waves. The device is called AutEMsys. It does not cut, and it does not poison. It delivers personalized, amplitude-modulated electromagnetic frequencies through the body, tuned to specific cancers the way a dial finds a station. The man running it is Michael Choukas, and he is not a physicist. He is the person who spent a career proving, with data, whether oncology treatments do what they claim. That is the interesting part.
Choukas co-founded Autem Therapeutics in 2022 with Frederico Costa, a physician-scientist working out of Brazil. The pairing tells you the shape of the thing: a clinical researcher who had the science, and an operator who had spent twenty years turning oncology evidence into businesses. Most founders pitch a hunch. Choukas had already lived on the receiving end of every claim a cancer company ever made - and he signed up anyway.
"Our team is passionate about developing a non-invasive, non-toxic, globally accessible cancer treatment to enhance the outcomes and lives of cancer patients worldwide."
The operator's resume
Before Autem, Choukas built and ran the unglamorous, essential machinery of modern oncology: the evidence layer. He was President of Outcomes Science and Services at Concerto HealthAI (now ConcertAI), and before that CEO of its predecessor, Vector Oncology - companies whose whole job was to measure, with real-world data and analytics, what treatments accomplish once they leave the trial and meet actual patients. His resume reads like a tour of the field's back office: United BioSource, SCIREX, Oncopartners, and, at the very start, Bain & Company. He credits that company-building work with contributing to more than $2.5 billion in market value.
It is a particular kind of expertise. Spend long enough verifying other people's cancer claims and you develop a finely tuned instrument for spotting the ones that hold up. Choukas points that instrument at his own company now, which is either reassuring or terrifying depending on which side of the data you are standing on.
Why this, why now
The bet underneath Autem is not only scientific - it is geographic. Choukas talks about a treatment that works where the infrastructure does not: remote regions, places far from the nearest oncology center, patients a hospital cannot easily reach. A drug needs a cold chain and an infusion suite. A tunable field needs a device. If the science holds, the accessibility argument is the one that scales.
The company earned FDA Breakthrough Device designation for AutEMsys in advanced hepatocellular carcinoma - liver cancer - a signal from the regulator that the idea is worth a fast lane. Through 2025, Choukas steered Autem toward Investigational Device Exemption clearances to open clinical trials in liver cancer and glioblastoma. The work is far from finished. The device is not approved. That is the honest state of play, and Choukas, of all people, would be the first to say so.
"I'm excited to lead Autem's global management team which brings together experienced professionals with complementary expertise in oncology clinical practice and research, bio-physics, software development and AI, and medical device operations."
The shape of the bet
There is a quiet audacity to running a company like this from Hanover. No biotech corridor, no glass tower - a small headquarters in a town better known for its college than its cap tables, with the science and engineering humming away in Brazil and a medical and regulatory bench scattered across Germany, Canada and the United States. Fifteen or so people, two continents, one device. In 2025 Choukas even put Autem on stage as a live startup in the Venture Capital Investment Competition's MBA Northeast division, pitching student investors the way he once pitched real ones.
What makes Choukas worth watching is the direction of his career arc. The usual story runs the other way: scientists who learn to sell, founders who pick up operations as they go. Choukas already knew how to run things, already knew the evidence game cold, and chose - deliberately, in his fifties' worth of pattern recognition - to attach all of it to an unproven idea about frequencies and tumors. Most people with his track record buy the safe annuity. He took the swing.
Whether AutEMsys works is a question only the trials will answer, and Choukas has built his whole life around respecting that exact distinction - between what a company hopes and what its data shows. He is, in the end, a man trying to disprove himself in public. If the frequencies hold up, he will have helped move cancer care somewhere genuinely new. If they do not, he will be the first to read it in the numbers. Either way, he is catching up to no one. He is mid-stride.